Navigation Links
Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award

VEDBAEK, Denmark, July 24 /PRNewswire-FirstCall/ -- Frost & Sullivan has announced the selection of Exiqon as the recipient of its 2008 Growth Strategy Leadership Award in the molecular diagnostic market. This award follows Frost & Sullivan's most recent analysis of the molecular diagnostic market.

Exiqon was selected for this award because of the company's acquisition of Oncotech, a market leader in the field of in vitro therapy selection testing for cancer. The research team at Frost & Sullivan viewed the acquisition of Oncotech by Exiqon as both well-timed and well-executed on the heels of the company's highly successful May 2007 IPO. .

The acquisition of Oncotech allowed the two companies to combine resources to become a leading supplier of molecular diagnostic tests based on proprietary miRNA biomarkers. "Combining the two companies has allowed Exiqon to master a number of the most significant challenges in building a platform for its future molecular diagnostic business in the US," says CEO Lars Kongsbak.

"We are dedicated to personalizing the treatment selection for cancer patients. This acquisition increases the likelihood of success and the speed in which new molecular diagnostic products can be marketed by Exiqon" continues Kongasbak; "Our goal is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment."

Through Oncotech, Exiqon markets diagnostic products that enable doctors to test whether their patients are resistant to chemotherapies prior to subscribing a treatment (the 'Extreme Drug Resistance-test'). Oncotech provides a strategic competitive advantage and a clear path to the market for Exiqon's new diagnostic products. Exiqon has already established itself as one of the market's leading providers of research products for gene expression analysis based on the LNA(TM) technology.

Frost & Sullivan does not accept nominations or submissions for Frost & Sullivan Awards. The selection of this Award comes through in-depth interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.

"Exiqon strategically gained entry into the U.S. cancer molecular diagnostics and allied pharmaceutical services market via its $45 million acquisition of privately-held Oncotech," explains Frost & Sullivan senior analyst Dr. Sudeep Basu. "The February 2008 all-share-deal also strengthens Exiqon's position in the overall U.S. life sciences research and clinical diagnostics markets."

"Pharmaceutical companies now have a rapidly growing interest in biomarker development and companion diagnostics," continues Exiqon CEO Kongsbak. "Exiqon's proficiency in High Throughput Screening (HTS), together with a Bio-Bank of 150,000 tumor tissue samples at Oncotech, positions Exiqon as a partner-of-choice for pharmaceutical companies."

"Exiqon's well-executed market entry strategy, continued focus on innovation, key partnerships with industry and cancer research centers, and market-driven product development approach position Exiqon as a leader in its industry," adds Frost & Sullivan's Dr. Basu.

About Exiqon

Exiqon combines leading-edge scientific expertise in gene expression with proprietary LNA(TM) technology. The company's products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, the company addresses the unmet need for a new approach to the diagnosis of cancer. Exiqon markets its products directly on, or through distributors (, and partners its proprietary Locked Nucleic Acids (LNA(TM)) technologies through industry leaders. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark and is listed on the NASDAQ OMX in Copenhagen.

About Frost & Sullivan Best Practices Awards

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

Additional information, Exiqon:

Lars Kongsbak, CEO, phone +45-45-66-08-88 (cell: +45-40-90-21-01)

Hans Henrik Chrois Christensen, CFO, phone +45-45-66-08-88 (cell: +45-40-90-21-31)

Additional information, Frost & Sullivan:

Frost & Sullivan, Jake Wengroff, Director, Corporate Communications Phone: +1-917-952-6816

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
2. Exiqon: Major Shareholder Announcement
3. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
4. Spherix Receives NASDAQ Bid Price Deficiency Letter
5. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
6. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
7. Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Lorus Therapeutics Receives $600 Thousand From Escrow Account
10. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
11. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
Post Your Comments:
(Date:10/9/2015)... Pa. and ROCKVILLE, Md. ... Inc. ("ITI"), a privately-held biotechnology company developing next ... announced that it has entered into an exclusive ... LAMP-vax products for the treatment or prevention of ... execution of the agreement, Immunomic Therapeutics will receive ...
(Date:10/9/2015)... ... October 09, 2015 , ... Leading microbial genomics startup uBiome today ... understand the relationship between weight management and the microbiome. The study uses the ResearchKit ... using an iPhone app. , The uBiome app is available as a free download ...
(Date:10/8/2015)... -- Genetic testing for mutations beyond those currently recommended in ... at risk of having a child with cystic fibrosis, ... American Society of Human Genetics (ASHG) Annual Meeting, which ... . The study is one of four that ... presenting at the conference this week demonstrating the clinical ...
(Date:10/8/2015)... BALTIMORE, Maryland , October 8, 2015 /PRNewswire/ ... .   --> Goldman ... specializing in the small cap and microcap sectors, ... sponsored research report on PharmaCyte Biotech, Inc. (OTCQB ... company focused on developing and preparing treatments for ...
Breaking Biology Technology:
... (, ) announced today the publication ... written and edited by Richard S. Lord and ... by Bralley and Lord, Laboratory,Evaluations in Molecular Medicine, ... arm of Metametrix Inc., a leader in nutritional ...
... Exemplary Work ... of Oncology ... winner,and finalists of its 2008 Extraordinary Healer Award for Oncology ... Annual,Congress. Ortho Biotech Products, L. P. sponsored the award, which ...
... Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announced today that ... study of intravenous REOLYSIN(R) in patients with,sarcomas metastatic ... Society of,Clinical Oncology (ASCO) website at ... . The abstract is entitled "A Phase II,Study ...
Cached Biology Technology:
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:10/1/2015)... , Oct. 1, 2015  Biometrics includes ... analysing human body characteristics, such as fingerprints, eye ... purposes. Adoption of biometrics technology has been constantly ... the last five years. In addition to the ... is fingerprint recognition, other means of biometric authentication ...
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
Breaking Biology News(10 mins):
... blended biodiesel fuels purchased from small-scale retailers, researchers at ... the blends do not contain the advertised amount of ... sampled pure biodiesel and blends from more than a ... listed as 20 percent biodiesel (commonly known as B20), ...
... complex has multiple causes. It,s sometimes hard to classify ... than any other disease -- an estimated $690 million ... a team of Kansas State University researchers is stepping ... Department of Agriculture, the team is analyzing data from ...
... and wisest mythology allude to the snake as a ... legend surrounding this proverbial predator may not be based ... Virginia recently discovered, the common fear of snakes is ... were capable of surviving the dangers of an uncivilized ...
Cached Biology News:
Human ABCG2 MAb (Clone 5D3)...
... purified Formulation: 50mM Tris-HCl, pH ... 0.2mM PMSF, 1mM benzamidine, 0.1% ... PP2A1 (Protein Phosphatase 2A1) partially ... sulfate precipitation, QSepharose,amino-hexyl agarose, Superdex ...
... The Beacon 2000 One-Step FP Standardization ... high and low fluorescence polarization values ... of the Beacon 2000 System. It ... polarization values generated by their instrument ...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
Biology Products: